Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance
David C. Turner, Julie A. Stone(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lokesh Jain(Merus (Netherlands)), Kapil Mayawala(Merck & Co., Inc., Rahway, NJ, USA (United States)), Andrew Robinson(University of California, Riverside), Edward B. Garon(University of California, Los Angeles), Anna Kondic(Merck & Co., Inc., Rahway, NJ, USA (United States)), Dinesh P. de Alwis(Merck & Co., Inc., Rahway, NJ, USA (United States)), Keaven M. Anderson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jonathan W. Riess(Comprehensive Blood & Cancer Center), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jiannan Kang(Hebei University), Vikram Sinha(United States Food and Drug Administration)
Cited by 216
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Cardiovascular disease risk profiles
|American Heart Journal|1991|2.2k
An updated coronary risk profile. A statement for health professionals.
|Circulation|1991|1.9k